Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lesko

Showing results (131-140 of 231) with videos related to

Pageof 24
Sort By:
Journal of Pharmaceutical Sciences|November 1, 1979
Pharmacokinetics and relative bioavailability of oral theophylline capsulesL J Lesko, A T Canada, G Eastwood, et al.
The Pharmacogenomics Journal|July 26, 2005
The need for education in pharmacogenomics: a regulatory perspectiveF W Frueh, F Goodsaid, A Rudman, et al.
Frontiers in Pharmacology|August 9, 2020
Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis TherapySonja Hartmann, Konstantinos Biliouris, Lawrence J Lesko, et al.
Personalized Medicine|May 24, 2018
Pharmacogenomics and adverse drug reactionsShashi Amur, Issam Zineh, Darrell R Abernethy, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1984
Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatographyD Fiore, F A Auger, G L Drusano, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 23, 2001
Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies?W W Hauck, A Parekh, L J Lesko, et al.
Journal of Clinical Pharmacology|January 31, 2009
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunityMyong-Jin Kim, Shiew-Mei Huang, Urs A Meyer, et al.
Drug Intelligence & Clinical Pharmacy|February 1, 1983
Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacyA T Canada, L J Lesko, C I Haffajee, et al.
Clinical Pharmacology and Therapeutics|June 28, 2002
Effect of St John's wort on the pharmacokinetics of fexofenadineZaiqi Wang, Mitchell A Hamman, Shiew-Mei Huang, et al.
British Journal of Pharmacology|April 27, 2020
Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entitiesRaja Venkatasubramanian, Teresa A Collins, Lawrence J Lesko, et al.
Pageof 24

Showing results (131-140 of 231) with videos related to

Sort By:
Pageof 24
Journal of Pharmaceutical Sciences|November 1, 1979
Pharmacokinetics and relative bioavailability of oral theophylline capsulesL J Lesko, A T Canada, G Eastwood, et al.
The Pharmacogenomics Journal|July 26, 2005
The need for education in pharmacogenomics: a regulatory perspectiveF W Frueh, F Goodsaid, A Rudman, et al.
Frontiers in Pharmacology|August 9, 2020
Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis TherapySonja Hartmann, Konstantinos Biliouris, Lawrence J Lesko, et al.
Personalized Medicine|May 24, 2018
Pharmacogenomics and adverse drug reactionsShashi Amur, Issam Zineh, Darrell R Abernethy, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1984
Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatographyD Fiore, F A Auger, G L Drusano, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 23, 2001
Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies?W W Hauck, A Parekh, L J Lesko, et al.
Journal of Clinical Pharmacology|January 31, 2009
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunityMyong-Jin Kim, Shiew-Mei Huang, Urs A Meyer, et al.
Drug Intelligence & Clinical Pharmacy|February 1, 1983
Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacyA T Canada, L J Lesko, C I Haffajee, et al.
Clinical Pharmacology and Therapeutics|June 28, 2002
Effect of St John's wort on the pharmacokinetics of fexofenadineZaiqi Wang, Mitchell A Hamman, Shiew-Mei Huang, et al.
British Journal of Pharmacology|April 27, 2020
Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entitiesRaja Venkatasubramanian, Teresa A Collins, Lawrence J Lesko, et al.
Pageof 24